ICH Q11 Starting Material Justification — Global Convergence and Remaining Regulatory Differences

ICH Q11 was designed to harmonize starting material selection for drug substances globally. FDA, EMA, and PMDA all implement it. They do not implement it identically.

A starting material accepted by FDA at five synthetic steps from the drug substance, justified by an impurity fate and purge analysis and a significant-structural-fragment argument, can still be challenged by EMA at the MAA Day 70 assessment, whose Q&A document interprets that structural criterion more conservatively. PMDA may reject the same starting material outright because it isn’t a commercially available chemical entity from a listed supplier. The starting material decision gets made early in development, when regulatory pressure is low. The consequences of getting the multi-agency picture wrong arrive at Day 70.

ICH Q11 Starting Material Criteria — The Significant Structural Fragment Test, the Step Distance FDA and EMA Interpret Differently, and PMDA’s Commercial Availability Requirement

ICH Q11 sets three core criteria for starting material selection: the material must incorporate a significant structural fragment of the drug substance, recognizable in the core scaffold, ring system, key functional group, or stereocenter; it must be commercially available, or justified as a controlled non-commercial intermediate with at least two qualified suppliers; and its specification must provide adequate quality assurance for everything synthesized downstream under GMP. The first criterion is where FDA and EMA genuinely diverge in application. FDA applies a largely qualitative test, asking whether the starting material’s structure contributes meaningfully to the drug substance. EMA’s Question and Answer document on ICH Q11 adds a semi-quantitative dimension, weighing structural contribution against the number of synthetic steps separating the starting material from the drug substance. A concrete case shows the gap: a drug substance at 500 Da molecular weight, with a proposed starting material at five steps upstream carrying 200 Da, a 40% molecular weight contribution, may satisfy FDA’s structural contribution standard outright, while EMA’s assessors are likely to request additional justification for that five-step distance, particularly where the starting material doesn’t contain the drug substance’s primary pharmacophore. PMDA introduces an entirely separate constraint that neither FDA nor EMA applies the same way: PMDA’s position is that an intermediate manufactured exclusively for a single drug substance program doesn’t qualify as a starting material at all, regardless of how well it satisfies the structural significance test, and PMDA generally expects a starting material for a simple linear synthetic route to sit no more than three to a sufficient downstream process under the applicant’s control, justified against all ICH Q11 principles rather than a fixed step count from the drug substance, sourced from at least two independent commercial suppliers.

SM Specification Design for Global Submissions — Assay, Chiral Purity, ICH M7 Mutagenic Impurity Limits, and the EMA-Specific Tighter Limit Adoption That Avoids Dual Specification Management

A starting material specification built for global use has to control identity by IR and, where a stereocenter carries through to the drug substance’s own stereochemistry, chiral purity by chiral HPLC, commonly at 99.0% enantiomeric excess or above. Assay by HPLC at 99.5% or better is standard for a starting material of established quality, alongside process impurity control at the ICH Q3A reporting threshold of 0.10%, tightened wherever ICH M7 identifies a genotoxic structural alert, residual solvent limits per ICH Q3C, elemental impurity limits per ICH Q3D, and water content control by Karl Fischer where hygroscopicity matters. The practical decision point arises when EMA requests a tighter limit than the ICH Q3A default, commonly down to a 0.05% detection limit for a specific process impurity carrying a genotoxic structural alert that EMA’s assessor judges inadequately controlled by the synthesis as filed. The more defensible response isn’t maintaining two specifications, an FDA-filed version at the standard threshold and an EMA-filed version at the tighter limit, it’s adopting the tighter EMA-driven limit as the single global specification used in both filings. Two specifications for the same starting material across two markets creates exactly the kind of divergent-limit management burden that a harmonized global CMC package is meant to avoid, and the incremental cost of the tighter limit is generally far smaller than the ongoing operational cost of running two parallel specification regimes indefinitely.

Impurity Fate and Purge Analysis — ICH M7 TTC Calculation, Step-by-Step Purge Factor, and the SM Specification Back-Calculation When the Purge Is Inadequate

The starting material justification under ICH Q11 depends on a fate and purge analysis demonstrating that impurities introduced before the starting material step, in the non-GMP portion of the synthesis, are adequately controlled in the finished drug substance by the downstream GMP steps. For a mutagenic impurity identified by structural alert, that means quantifying the purge factor contributed by each downstream operation, crystallization, wash, recrystallization, and confirming the cumulative purge brings the impurity to or below the ICH M7 threshold of toxicological concern, 1.5 μg per day at the maximum daily dose. The arithmetic makes the stakes concrete: a mutagenic impurity present at 500 ppm in the starting material, carried into a drug substance dosed at 200 mg per day with no purge at all, would deliver 100 μg per day of that impurity, more than sixty times the 1.5 μg/day TTC. Achieving compliance without any purge credit would require the impurity’s starting-material-level limit alone to fall to roughly 1 ppm or below; if the actual purge analysis instead demonstrates 99.7% cumulative removal across the downstream steps, that same 500 ppm starting level resolves to a compliant drug substance level without requiring the starting material specification itself to be pushed to an unrealistically tight limit. Getting this analysis right, and documenting it with genuine step-by-step purge data rather than an assumed default, is what determines whether a starting material specification needs to carry an aggressive impurity limit or can rely on the demonstrated purge capacity of the synthesis that follows.

The XGene ICH Q11 Global Starting Material CMC Architecture — Selection Criteria, Agency Position Comparison, Specification Design, Purge Analysis Protocol, and 3.2.S.2 Justification Structure

The XGene ICH Q11 Global Starting Material CMC Architecture is a structured framework for starting material selection and justification across simultaneous FDA, EMA, and PMDA drug substance submissions.

1. SM Selection Criteria Assessment — Evaluate structural significance, step distance from the drug substance, and commercial availability against each agency’s specific interpretation before the selection is locked in. 2. FDA/EMA/PMDA Position Comparison Matrix — Map the proposed starting material against FDA’s qualitative structural test, EMA’s semi-quantitative distance weighting, and PMDA’s commercial-entity and step-distance requirements simultaneously. 3. SM Specification Design for Global Submissions — Build assay, chiral purity, and impurity limits to satisfy the most stringent agency position from the outset, adopting any EMA-driven tighter limit as the single global specification. 4. Impurity Fate and Purge Analysis Protocol — Quantify step-by-step purge factors for every ICH M7 structural alert identified before the starting material step, comparing cumulative purge against the TTC rather than assuming adequate control by default. 5. 3.2.S.2 Justification Narrative Structure — Document structural significance, commercial availability, GMP scope rationale, and impurity control strategy as a unified narrative built to withstand all three agencies’ review standards.

The output is the starting material selection and specification strategy that anticipates FDA, EMA, and PMDA divergence before submission, rather than discovering it through a Day 70 assessment question or a PMDA request to relocate the GMP starting point.

ICH Q11: Development and Manufacture of Drug Substances (2012) establishes the significant structural fragment, commercial availability, and specification adequacy criteria this article’s analysis is built around. The EMA Questions and Answers on the ICH Q11 Guideline (2015) establishes EMA’s semi-quantitative distance interpretation that diverges from FDA’s qualitative structural assessment, while PMDA’s Pharmaceutical Interview Guidance establishes the commercial-entity requirement and the three-to-four-step distance expectation that can disqualify a starting material FDA and EMA would otherwise accept. ICH M7(R1) (2017) establishes the mutagenic impurity TTC framework, 1.5 μg/day, that governs the impurity fate and purge analysis underlying starting material justification.

For your drug substance development program, have you compared your proposed starting material against FDA, EMA, and PMDA selection criteria specifically, confirmed whether it sits within EMA’s preferred distance from the drug substance, verified it qualifies as a commercially available chemical entity for PMDA purposes, and confirmed your impurity fate and purge analysis covers every ICH M7 structural alert present in the pre-starting-material synthesis?